Strong in vitro activities of two new rifabutin analogs against multidrug-resistant Mycobacterium tuberculosis

Antimicrobial Agents and Chemotherapy

Volumn 54, Issue 12, 2010, Pages 5363-5365

  García, Ana Belén ^a   Palacios, Juan J ^b   Ruiz, María Jesús ^c   Barluenga, José ^a   Aznar, Fernando ^a   Cabal, María Paz ^a   García, José María ^d   Díaz, Natalia ^a  

^a UNIVERSITY OF OVIEDO   (Spain)

^b HOSPITAL UNIVERSITARIO CENTRAL DE ASTURIAS   (Spain)

^c HOSPITAL GENERAL UNIVERSITARIO GREGORIO MARAÑÓN   (Spain)

^d HOSPITAL SAN AGUSTÍN   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFECTIVE AGENT; RFA 1; RFA 2; RIFABUTIN; UNCLASSIFIED DRUG;

ANTIBACTERIAL ACTIVITY; ARTICLE; BACTERIAL STRAIN; IN VITRO STUDY; MULTIDRUG RESISTANCE; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; PRIORITY JOURNAL;

ANTIBIOTICS, ANTITUBERCULAR; DRUG RESISTANCE, MULTIPLE, BACTERIAL; MICROBIAL SENSITIVITY TESTS; MOLECULAR STRUCTURE; MYCOBACTERIUM TUBERCULOSIS; RIFABUTIN;

EID: 78649654380     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.00149-10     Document Type: Article

References (16)

1. Barluenga, J., F. Aznar, M.-P. Cabal, A.-B. García, and C. Valdés. May 2007. Spiropiperidyl rifamycins for the treatment of mycobacterial infections. European patent EP 1 783 129 A1. U.S. patent US 7,521,458 B2.
2. Barluenga, J., F. Aznar, A.-B. García, M.-P. Cabal, J. J. Palacios, and M. A. Menéndez. 2006. New rifabutin analogs: synthesis and biological activity against Mycobacterium tuberculosis. Bioorg. Med. Chem. Lett. 16:5717-5722.
3. Bryskier, A., and J. Lowther. 2005. Fluoroquinolones and tuberculosis: a review, p. 1124-1145. In A. Bryskier (ed.), Antimicrobial agents: antibacterials and antifungals. ASM Press, Washington, DC.
4. Campbell, E. A., O. Pavlova, N. Zenkin, F. Leon, H. Irschik, R. Jansen, K. Severinov, and S. A. Darst. 2005. Structural, functional, and genetic analysis of sorangicin inhibition of bacterial RNA polymerase. EMBO J. 24:674-682.
5. Corbett, E. L., C. J. Watt, J. Catherine, N. Walker, D. Maher, and B. G. Williams. 2003. The growing burden of tuberculosis: global trends and interactions with the HIV epidemic. Arch. Intern. Med. 163:1009-1021.
6. Dye, C., M. A. Espinal, C. J. Watt, C. Mbiaga, and B. G. Williams. 2002. Worldwide incidence of multidrug-resistant tuberculosis. J. Infect. Dis. 185:1197-1202.
7. Floss, H. G., and T. W. Yu. 2005. Rifamycin - mode of action, resistance, and biosynthesis. Chem. Rev. 105:621-632.
8. Gardner, C. A., T. Acharya, and A. Pablos-Méndez. 2005. The global alliance for tuberculosis drug development - accomplishments and future directions. Clin. Chest Med. 26:341-347.
9. Marsili, L., C. R. Pasqualucci, A. Vi, B. Gioia, G. Schiopacassi, and G. Oronzo. 1981. New rifamycins modified at positions 3 and 4 synthesis, structure and biological evaluation. J. Antib. 34:1033-1038.
10. National Committee for Clinical Laboratory Standards. 2003. Susceptibility testing of mycobacteria, nocardiae, and other aerobic actinomycetes. Approved standard M24-A. National Committee for Clinical Laboratory Standards, Wayne, PA.
11. O'Brien, R. J., and M. Spigelman. 2005. New drugs for tuberculosis: current status and future prospects. Clin. Chest Med. 26:327-340.
12. Rubio, E., I. Merino, A.-B. García, M.-P. Cabal, C. Ribas, and M. Bayod-Jasanada. 2005. NMR spectroscopic analysis of new spiro- piperidylrifamycins. Magn. Reson. Chem. 43:269-282.
13. Sensi, P. 1975. Recent progress in the chemistry and biochemistry of rifamycins. Pure Appl. Chem. 41:15-29.
14. Telenti, A., P. Imboden, F. Marchesi, D. Lowrie, S. Cole, M. J. L. Colston, L. Matter, K. Schopfer, and T. Bodmer. 1993. Detection of rifampicin-resistance mutations in Mycobacterium tuberculosis. Lancet 341:647-650.
15. Williams, B. G., and C. Dye. 2003. Antiretroviral drugs for tuberculosis control in the era of HIV/AIDS. Science 301:1535-1537. (Pubitemid 37128545)
16. World Health Organization. 2008. WHO report 2008. Global tuberculosis control: surveillance, planning, financing. WHO/HTM/TB/2008.393. World Health Organization, Geneva, Switzerland.